Gundavda Kaival K, Patkar Shraddha, Varty Gurudutt P, Shah Niket, Velmurugan Karthik, Goel Mahesh
Department of Gastrointestinal and Hepatobiliary Surgery, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India.
Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India.
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102401. doi: 10.1016/j.jceh.2024.102401. Epub 2024 Aug 10.
Hepatocellular carcinoma (HCC) represents a significant global health burden. Surgery remains a cornerstone in the curative treatment of HCC, and recent years have witnessed notable advancements aimed at refining surgical techniques and improving patient outcomes. This review presents a detailed examination of the recent innovations in HCC surgery, highlighting key developments in both surgical approaches and adjunctive therapies. Advanced imaging technologies have revolutionized preoperative assessment, enabling precise tumour localization and delineation of vascular anatomy. The use of three-dimensional rendering has significantly augmented surgical planning, facilitating more accurate and margin-free resections. The advent of laparoscopic and robotic-assisted surgical techniques has ushered in an era of minimal access surgery, offering patients the benefits of shorter hospital stays and faster recovery times, while enabling equivalent oncological outcomes. Intraoperative innovations such as intraoperative ultrasound (IOUS) and fluorescence-guided surgery have emerged as valuable adjuncts, allowing real-time assessment of tumour extent and aiding in parenchyma preservation. The integration of multimodal therapies, including neoadjuvant and adjuvant strategies, has allowed for 'bio-selection' and shown the potential to optimize patient outcomes. With the advent of augmented reality and artificial intelligence (AI), the future holds immense potential and may represent significant strides towards optimizing patient outcomes and refining the standard of care.
肝细胞癌(HCC)是一项重大的全球健康负担。手术仍然是HCC根治性治疗的基石,近年来在优化手术技术和改善患者预后方面取得了显著进展。本综述详细探讨了HCC手术的最新创新,重点介绍了手术入路和辅助治疗方面的关键进展。先进的成像技术彻底改变了术前评估,能够精确进行肿瘤定位并描绘血管解剖结构。三维重建技术的应用显著增强了手术规划,有助于更准确地进行无切缘切除。腹腔镜和机器人辅助手术技术的出现开创了微创外科手术时代,为患者带来了住院时间缩短和恢复更快的好处,同时实现了相当的肿瘤学疗效。术中超声(IOUS)和荧光引导手术等术中创新已成为有价值的辅助手段,可实时评估肿瘤范围并有助于保留实质组织。包括新辅助和辅助策略在内的多模式治疗的整合实现了“生物选择”,并显示出优化患者预后的潜力。随着增强现实和人工智能(AI)的出现,未来前景广阔,可能朝着优化患者预后和完善治疗标准迈出重大步伐。